Nanoparticle Delivery of Novel PDE4B Inhibitor for the Treatment of Alcoholic Liver Disease
The incidence of alcoholic liver disease (ALD) is increasing worldwide while no effective treatment has been approved. The progression of ALD has proven to be related to the upregulation of phosphodiesterase 4 (PDE4) expression, and PDE4 inhibitors showed potential to improve ALD. However, the appli...
Saved in:
Main Authors: | Jingyi Ma (Author), Virender Kumar (Author), Ram I. Mahato (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review
by: Andrew Blauvelt, et al.
Published: (2023) -
Genotoxic potential of a novel PDE-4B inhibitor Apremilast by chromosomal aberration and micronucleus assay in mice
by: Muhammad Afzal, et al.
Published: (2020) -
A Novel Catecholopyrimidine Based Small Molecule PDE4B Inhibitor Suppresses Inflammatory Cytokines in Atopic Mice
by: Baskaran Purushothaman, et al.
Published: (2018) -
The anti-depressant effects of a novel PDE4 inhibitor derived from resveratrol
by: Yingcong Yu, et al.
Published: (2021) -
Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
by: Jonathan E. Phillips
Published: (2020)